Research & Development: Page 62
-
PharmaVoice Team/PharmaVoice
Patient-Centric Clinical Trials: Fad, Trend, or Future?
Patient-Centric Clinical Trials: Fad, Trend, or Future? One of the prominent topics of discussion in biopharmaceutical R&D during the past few years has centered on methods for improving patient management in clinical trials. While clinical trials have always focused on patients, only recentl...
By Todd Kole • May 29, 2012 -
PharmaVoice Team/PharmaVoice
Top 10 Patient Enrollment and Retention Myths
Top 10 Patient Enrollment and Retention Myths Myths can Lead to Misses Today’s trial climate frustrates many clinical study teams. Operations must deliver quality trial data under intense pressures. Larger, longer, and more esoterically designed trials place a strain on patient enrollment and ret...
By Scott H. Connor • May 29, 2012 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Safety Panels: Combining the Conventional and Novel Toxicity Biomarkers
Safety Panels: Combining the Conventional and Novel Toxicity Biomarkers The notion of biomarker is not new. The FDA defines a biomarker as the measurable endpoint that can be used as an indicator of a physiological or pathological process. In particular, toxicity biomarkers are those capable of d...
By Maria-Magdalena Patru • May 29, 2012 -
PharmaVoice Team/PharmaVoice
2012 DIA Preview
2012 DIA Preview New tools, services, and products to improve drug development from DIA exhibitors. This special Drug Information Association section highlights news as well as new and innovative products being offered by companies exhibiting at the upcoming 2012 DIA, the 48th Annual Meeting, in ...
By Taren Grom • May 29, 2012 -
PharmaVoice Team/PharmaVoice
UpFront
UpFront Awards… Octagon receives PACT award Octagon Research Solutions has been named Emerging Life Sciences Company of the Year by the Greater Philadelphia Alliance for Capital and Technologies (PACT). The award honors growing companies in the region’s life-sciences industry that demonstrated cl...
By Taren Grom • May 28, 2012 -
PharmaVoice Team/PharmaVoice
HBA's 2012 Rising Stars
Meet the 105 Healthcare Businesswomen’s Association’s Rising Stars… By Taren Grom, Editor HBA’s 2012 Rising Stars These high-potential women, who represent all facets and disciplines of the life-sciences industry, are being recognized by their companies for: H Significantly contributing to th...
By PharmaVoice Team • April 27, 2012 -
PharmaVoice Team/PharmaVoice
The Sun Keeps Rising on Japan's Pharma Industry
Kim Ribbink Japan’s numerous universities and research institutions, cutting-edge research, state-of-the-art technology, and high-quality manufacturing facilities are the hallmarks of a leading market for the pharmaceutical industry. Japan is one of the world’s lead developers of pharmaceutica...
By Kim Ribbink • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Addressing Reimbursement During Development
Denise Myshko Pharma companies are experiencing greater scrutiny from government, private payers, and consumers. Creating a comprehensive reimbursement plan that begins at early phases of product development is essential in successfully obtaining coverage. Increasingly in the United States and in...
By Denise Myshko • April 27, 2012 -
PharmaVoice Team/PharmaVoice
New Course for Biotherapeutics
Denise Myshko Companies developing biotherapeutics are beginning to study indications beyond cancer and autoimmune and infectious diseases and are researching how antibodies and proteins can be used to treat other conditions, such as pain and cardiovascular conditions, that have traditionally bee...
By Denise Myshko • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
Word Building Strong Partnerships John Gargiulo, President and CEO of Daiichi Sankyo Inc., talks about how a philanthropic gift 100 years ago led to a global collaboration for drug development. PV: What is Daiichi Sankyo’s connection to Washington, D.C.’s cherry trees? Gargiulo: One hundred year...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
Talent Pool executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Dr. Charlotte KREMER Astellas Names Global Medical Affairs Head Charlotte Kremer, M.D., has joined Astellas Pharma as head of the global medical affairs organization. Dr. Kremer wa...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
Tools of the Trade
Tools of the Trade New electronic and web-based applications, sites, and technologies By Carolyn Gretton New Tool from HealthSTAR Provides Virtual Bridge Between KOLs, HCPs Trend: New advances in digital platforms are allowing for the capture of peer-to-peer programs via a digital platform that ...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Pharma Trax Sales, marketing, And R&D?Trends affecting the healthcare industry By Carolyn Gretton GSMA Forecasts Robust Mobile Health Market Growth Areport conducted by PwC for the GSMA predicts the growth of the mobile health (mHealth) market will result in $23 billion worth of revenue oppor...
By Carolyn Gretton • April 27, 2012 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: IRBs: Remaking the Rules
By Carolyn Gretton Institutional review boards (IRBs) and research compliance offices remain at the forefront of providing responsible protection of human subjects within the research environment, but the differences in how each group interprets and implements these responsibilities can directly ...
By Carolyn Gretton • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Global Patient Recruitment
Robin Robinson Social media, regulations, and outsourcing are shaping global trial recruitment models. According to a recent CEI survey, more than 20% of responding companies use text messaging for patient visit reminders in Phase I through Phase III. Source: Cutting Edge Information As is tru...
By Taren Grom • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Clinical Trial Technology Continues to Evolve
By Denise Myshko Electronic processes for data collection are now widely used in clinical trials. But the use of technology and electronic processes for the operational side of trials is still lagging. Ten years ago, when PharmaVOICE first started writing about clinical trial technologies, elect...
By Denise Myshko • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Patient Communities: Getting to Know You
Patient Communities: Getting to Know You By Robin Robinson The industry is tapping into the wealth of market research available through patient communities. In 2010, UCB and PatientsLikeMe launched a patient community designed as an online forum for epilepsy patients to share their experiences in...
By Robin Robinson • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Last Word
The Promise of Stem Cell Therapies for Chronic Diseases Andrew Pecora, M.D., Chief Medical Officer and Director at Neostem, discusses the company’s work using stem cells for cardiovascular conditions. The company’s lead product candidate, AMR-001, is for the preservation of heart function after a...
By Dr. Andrew Pecora • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Talent Pool
executive appointments and promotions in the healthcare industry By Carolyn Gretton Pharmaceutical POOL Dr. Rob KOREMANS Former Sanofi VP Takes Lead Role at Teva Europe Teva Pharmaceutical Industries has appointed Rob Koremans, M.D., to succeed Dr. Gerard van Odijk as president and CEO, Teva Euro...
By Carolyn Gretton • March 26, 2012 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry Study Explores How Consumers Interact With Pharma Companies Trend: Growing numbers of patients are turning to social media and digital tools to obtain drug information before meeting with their physicians, representing a key ...
By Carolyn Gretton • March 26, 2012 -
PharmaVoice Team/PharmaVoice
What's New
New healthcare-related products, services, and companies Transparency Life Sciences Launches with Open Innovation-Based Model Trend: This new breed of drug development company aims to achieve much greater efficiency in its patient-centric trials by harnessing the power of collaborative intellige...
By Carolyn Gretton • March 26, 2012 -
PharmaVoice Team/PharmaVoice
UpFront
Upfront Awards… CSL Honored for Work in Rare Diseases CSL Behring is the recipient of a 2012 European Organization for Rare Diseases Award for its work in developing and manufacturing therapies used to treat rare and serious medical conditions. One of the primary criteria for the award is a...
By Taren Grom • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The forum for the industry executive Volume 12 • Number 4 Publisher Lisa Banket Editor Taren Grom Creative Director Marah Walsh Managing EDitor Denise Myshko Senior EDitor Robin Robinson features EDitor Kim Ribbink Contributing Editor Carolyn Gretton design associate Ariel Medel national account ...
By Taren Grom • March 26, 2012 -
PharmaVoice Team/PharmaVoice
Germany: A Market for Clinical Research
G ermany is a pre-eminent pharmaceutical market. In 2008, for example, the German pharmaceutical industry comprised 243 companies, employed 126,000 people, and generated EUR 41.5 billion ($53.8 billion) in revenue, according to Germany Trade & Invest, a German investment agency. Germany is th...
By Kim Ribbink • Feb. 27, 2012 -
PharmaVoice Team/PharmaVoice
Payers Play Larger Role In PostLaunch Strategies
The focus of postlaunch activities has changed dramatically in just a few short years. Robin Robinson Due to the increased power of payers and managed care companies, Phase IV studies have become more imperative to sustaining a successful postlaunch campaign. Companies have had to reprioritize th...
By Robin Robinson • Feb. 26, 2012
Previous
